These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 25868746)

  • 21. De novo design, synthesis and biological evaluation of 1,4-dihydroquinolin-4-ones and 1,2,3,4-tetrahydroquinazolin-4-ones as potent kinesin spindle protein (KSP) inhibitors.
    Jiang C; Yang L; Wu WT; Guo QL; You QD
    Bioorg Med Chem; 2011 Sep; 19(18):5612-27. PubMed ID: 21856161
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fluorinated quinazolinones as potential radiotracers for imaging kinesin spindle protein expression.
    Holland JP; Jones MW; Cohrs S; Schibli R; Fischer E
    Bioorg Med Chem; 2013 Jan; 21(2):496-507. PubMed ID: 23245569
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Kinesin spindle protein (KSP) inhibitors. Part 7: Design and synthesis of 3,3-disubstituted dihydropyrazolobenzoxazines as potent inhibitors of the mitotic kinesin KSP.
    Garbaccio RM; Tasber ES; Neilson LA; Coleman PJ; Fraley ME; Olson C; Bergman J; Torrent M; Buser CA; Rickert K; Walsh ES; Hamilton K; Lobell RB; Tao W; South VJ; Diehl RE; Davide JP; Yan Y; Kuo LC; Li C; Prueksaritanont T; Fernandez-Metzler C; Mahan EA; Slaughter DE; Salata JJ; Kohl NE; Huber HE; Hartman GD
    Bioorg Med Chem Lett; 2007 Oct; 17(20):5671-6. PubMed ID: 17804233
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ligand- and structure-based in silico studies to identify kinesin spindle protein (KSP) inhibitors as potential anticancer agents.
    Balakumar C; Ramesh M; Tham CL; Khathi SP; Kozielski F; Srinivasulu C; Hampannavar GA; Sayyad N; Soliman ME; Karpoormath R
    J Biomol Struct Dyn; 2018 Nov; 36(14):3687-3704. PubMed ID: 29064326
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage.
    Tao W; South VJ; Zhang Y; Davide JP; Farrell L; Kohl NE; Sepp-Lorenzino L; Lobell RB
    Cancer Cell; 2005 Jul; 8(1):49-59. PubMed ID: 16023598
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bioisosteric approach in designing new monastrol derivatives: an investigation on their ADMET prediction using in silico derived parameters.
    Hassan SF; Rashid U; Ansari FL; Ul-Haq Z
    J Mol Graph Model; 2013 Sep; 45():202-10. PubMed ID: 24080467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kinesin spindle protein (KSP) inhibitors. Part 2: the design, synthesis, and characterization of 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP.
    Fraley ME; Garbaccio RM; Arrington KL; Hoffman WF; Tasber ES; Coleman PJ; Buser CA; Walsh ES; Hamilton K; Fernandes C; Schaber MD; Lobell RB; Tao W; South VJ; Yan Y; Kuo LC; Prueksaritanont T; Shu C; Torrent M; Heimbrook DC; Kohl NE; Huber HE; Hartman GD
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1775-9. PubMed ID: 16439123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conformation-dependent ligand regulation of ATP hydrolysis by human KSP: activation of basal hydrolysis and inhibition of microtubule-stimulated hydrolysis by a single, small molecule modulator.
    Luo L; Carson JD; Molnar KS; Tuske SJ; Coales SJ; Hamuro Y; Sung CM; Sudakin V; Auger KR; Dhanak D; Jackson JR; Huang PS; Tummino PJ; Copeland RA
    J Am Chem Soc; 2008 Jun; 130(24):7584-91. PubMed ID: 18491908
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kinesin spindle protein (KSP) inhibitors in combination with chemotherapeutic agents for cancer therapy.
    Song H; Zhou S; Wang R; Li S
    ChemMedChem; 2013 Nov; 8(11):1736-49. PubMed ID: 23964020
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and pharmacological screening of a large library of 1,3,4-thiadiazolines as innovative therapeutic tools for the treatment of prostate cancer and melanoma.
    De Monte C; Carradori S; Secci D; D'Ascenzio M; Guglielmi P; Mollica A; Morrone S; Scarpa S; Aglianò AM; Giantulli S; Silvestri I
    Eur J Med Chem; 2015 Nov; 105():245-62. PubMed ID: 26498571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The novel kinesin spindle protein (KSP) inhibitor SB-743921 exhibits marked activity in in vivo and in vitro models of aggressive large B-cell lymphoma.
    Bongero D; Paoluzzi L; Marchi E; Zullo KM; Neisa R; Mao Y; Escandon R; Wood K; O'Connor OA
    Leuk Lymphoma; 2015; 56(10):2945-52. PubMed ID: 25860245
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells.
    Carter BZ; Mak DH; Woessner R; Gross S; Schober WD; Estrov Z; Kantarjian H; Andreeff M
    Leukemia; 2009 Oct; 23(10):1755-62. PubMed ID: 19458629
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proteomic analysis of annexin A2 phosphorylation induced by microtubule interfering agents and kinesin spindle protein inhibitors.
    Fernandez-Garcia B; Casado P; Prado MA; Ugarte-Gil LJ; Artime N; Cabal-Hierro L; Calvo E; López JA; Ramos S; Lazo PS
    J Proteome Res; 2010 Sep; 9(9):4649-60. PubMed ID: 20597553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis and bioevaluation of dihydropyrazolo[3,4-b]pyridine and benzo[4,5]imidazo[1,2-a]pyrimidine compounds as dual KSP and Aurora-A kinase inhibitors for anti-cancer agents.
    Fu RG; You QD; Yang L; Wu WT; Jiang C; Xu XL
    Bioorg Med Chem; 2010 Nov; 18(22):8035-43. PubMed ID: 20934346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Kinesin spindle protein inhibitors in cancer: a patent review (2008 - present).
    Jiang C; You Q
    Expert Opin Ther Pat; 2013 Dec; 23(12):1547-60. PubMed ID: 23978071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ARRY-520, a novel KSP inhibitor with potent activity in hematological and taxane-resistant tumor models.
    Woessner R; Tunquist B; Lemieux C; Chlipala E; Jackinsky S; Dewolf W; Voegtli W; Cox A; Rana S; Lee P; Walker D
    Anticancer Res; 2009 Nov; 29(11):4373-80. PubMed ID: 20032381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Synthesis and antitumor activity of novel tetrahydro-beta-carboline derivatives as KSP inhibitors].
    Ruan XQ; Chen M; Wu WT; You QD
    Yao Xue Xue Bao; 2013 Jul; 48(7):1119-23. PubMed ID: 24133978
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent progress in the identification and clinical evaluation of inhibitors of the mitotic kinesin KSP.
    Knight SD; Parrish CA
    Curr Top Med Chem; 2008; 8(10):888-904. PubMed ID: 18673173
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and evaluation of biphenyl compounds as kinesin spindle protein inhibitors.
    Holland JP; Kang A; Cohrs S; Selivanova SV; Milicevic Sephton S; Betzel T; Frey D; Wieser M; Jaussi R; Kammerer RA; Schibli R; Fischer E
    Chem Biodivers; 2013 Apr; 10(4):538-55. PubMed ID: 23576341
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis and evaluation of tetrahydroisoquinolines as new kinesin spindle protein inhibitors.
    Jiang C; You Q; Liu F; Wu W; Guo Q; Chern J; Yang L; Chen M
    Chem Pharm Bull (Tokyo); 2009 Jun; 57(6):567-71. PubMed ID: 19483335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.